UNASSIGNED: The treatment of transformed @entity706 (TRIL) often includes salvage chemotherapy (SC) and autologous stem cell transplant (ASCT). NCIC CTG LY12 is a randomized phase III trial comparing @entity136 , @entity619 , @entity900 (GDP) to @entity619 , @entity2592 , @entity900 (DHAP) prior to ASCT. This analysis compares the results of SC and ASCT for TRIL with de novo diffuse large @entity1892 (DL). Six hundred nineteen @entity1 with relapsed/refractory aggressive @entity1893 were randomized to GDP or DHAP; 87 @entity1 (14%) had TRIL and 429 (69%) had DLBCL. The response rate to SC was 47% in TRIL and 45% in DL (p=0.81). Transplantation rates were similar: TRIL: 53%; DL: 52% (p=1.0). With a median follow-up of 53 months, 4 year OS was 39% for TRIL and 41% for DL (p=0.78); 4 year EFS was 27% for TRIL and 27% for DL (p=0.83). Post-ASCT, 4 year EFS was 45% for TRIL and 46% for DL. Histology (TRIL or DL) was not a predictor of any outcome in multivariate models. @entity1 with relapsed or refractory TRIL and DLBCL have similar outcomes with SC and ASCT; this therapy should be considered the standard of care for @entity1 with TRIL who have received prior systemic chemotherapy. NCIC CTG LY12 is registered to www.clinicaltrials.gov as NCT00078949.

Salvage chemotherapy and autologous stem cell transplantation for transformed XXXX : a subset analysis of NCIC CTG LY12.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity706 :: ('MESH:D008223', 'Disease') :: ['indolent lymphoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B cell lymphoma'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity706 :: (MESH:D008223,Disease) :: ['indolent lymphoma']
